Literature DB >> 25260946

Prognostic impact of pulmonary artery systolic pressure in patients undergoing transcatheter aortic valve replacement for aortic stenosis.

Kalkidan Bishu1, Rakesh M Suri2, Vuyisile T Nkomo3, Garvan C Kane1, Kevin L Greason2, Guy S Reeder1, Verghese Mathew1, David R Holmes1, Charanjit S Rihal1, Rowlens M Melduni1.   

Abstract

Baseline pulmonary hypertension (PH) is a predictor of poor outcomes in patients with severe aortic stenosis (AS). Surgical aortic valve replacement is thought to alleviate PH. The aim of this study was to determine the prognostic impact of PH in patients who underwent transcatheter aortic valve replacement (TAVR). An observational cohort study was conducted using prospectively collected data on 277 consecutive patients with severe AS who underwent TAVR at the Mayo Clinic (Rochester, Minnesota) from November 1, 2008, to June 31, 2013. Clinical and echocardiographic data, pulmonary function characteristics, and outcomes stratified by tertiles of pulmonary artery systolic pressure (PASP) were analyzed. From 277 patients who underwent TAVR, 251 patients had PASP assessment at baseline. Those in the highest PASP tertile (PASP ≥49 mm Hg) had more severe chronic lung disease and worse diastolic dysfunction. Being in the highest PASP tertile was an independent predictor of long-term mortality (hazard ratio 2.88, 95% confidence interval 1.15 to 7.23). Patients in the highest PASP tertile had longer lengths of hospital stay, while other short-term outcomes (30-day mortality and readmission, stroke, prolonged ventilation, and reoperation for bleeding) were similar across PASP tertiles. TAVR was associated with a decrease in PASP in the highest PASP tertile at 1 week after the procedure (-8 ± 14 mm Hg) and at 3 months (-7 ± 15 mm Hg) compared with baseline. In conclusion, among patients with severe AS who underwent TAVR, higher baseline PASP was strongly associated with diastolic dysfunction and chronic lung disease. Patients with higher baseline PASP tolerated TAVR relatively well in the early postprocedural phase, with diminished long-term survival. PH should not disqualify patients with severe AS from consideration for TAVR.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25260946     DOI: 10.1016/j.amjcard.2014.08.019

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

Review 1.  Pulmonary Hypertension Due to Left Heart Disease: an Update.

Authors:  Mandar A Aras; Mitchell A Psotka; Teresa De Marco
Journal:  Curr Cardiol Rep       Date:  2019-05-27       Impact factor: 2.931

2.  Left atrial dysfunction as a determinant of pulmonary hypertension in patients with severe aortic stenosis and preserved left ventricular ejection fraction.

Authors:  Andreea Calin; Anca D Mateescu; Monica Rosca; Carmen C Beladan; Roxana Enache; Simona Botezatu; Iulian Cosei; Cosmin Calin; Marian Simion; Carmen Ginghina; Andreea C Popescu; Bogdan A Popescu
Journal:  Int J Cardiovasc Imaging       Date:  2017-07-15       Impact factor: 2.357

Review 3.  Severe Aortic Valve Stenosis and Pulmonary Hypertension: A Systematic Review of Non-Invasive Ways of Risk Stratification, Especially in Patients Undergoing Transcatheter Aortic Valve Replacement.

Authors:  Elke Boxhammer; Alexander E Berezin; Vera Paar; Nina Bacher; Albert Topf; Sergii Pavlov; Uta C Hoppe; Michael Lichtenauer
Journal:  J Pers Med       Date:  2022-04-08

4.  Outcomes of persistent pulmonary hypertension following transcatheter aortic valve replacement.

Authors:  Ahmad Masri; Islam Abdelkarim; Michael S Sharbaugh; Andrew D Althouse; Jeffrey Xu; Wei Han; Stephen Y Chan; William E Katz; Frederick W Crock; Matthew E Harinstein; Dustin E Kliner; Forozan Navid; Joon S Lee; Thomas G Gleason; John T Schindler; João L Cavalcante
Journal:  Heart       Date:  2017-09-29       Impact factor: 5.994

5.  Pulmonary Hypertension in Aortic and Mitral Valve Disease.

Authors:  Micha T Maeder; Lukas Weber; Marc Buser; Marc Gerhard; Philipp K Haager; Francesco Maisano; Hans Rickli
Journal:  Front Cardiovasc Med       Date:  2018-05-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.